- Home
- UPXI vs APVO Comparison
UPXI vs APVO Comparison
Compare UPXI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- APVO
- Stock Information
- Founded
- UPXI 2018
- APVO 2016
- Country
- UPXI United States
- APVO United States
- Employees
- UPXI N/A
- APVO N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- APVO Health Care
- Exchange
- UPXI Nasdaq
- APVO Nasdaq
- Market Cap
- UPXI 3.6M
- APVO 3.3M
- IPO Year
- UPXI 2021
- APVO N/A
- Fundamental
- Price
- UPXI $15.51
- APVO $0.67
- Analyst Decision
- UPXI
- APVO Strong Buy
- Analyst Count
- UPXI 0
- APVO 1
- Target Price
- UPXI N/A
- APVO $296.00
- AVG Volume (30 Days)
- UPXI 6.5M
- APVO 8.7M
- Earning Date
- UPXI 05-07-2025
- APVO 05-07-2025
- Dividend Yield
- UPXI N/A
- APVO N/A
- EPS Growth
- UPXI N/A
- APVO N/A
- EPS
- UPXI N/A
- APVO N/A
- Revenue
- UPXI $18,625,089.00
- APVO N/A
- Revenue This Year
- UPXI $299.03
- APVO N/A
- Revenue Next Year
- UPXI N/A
- APVO N/A
- P/E Ratio
- UPXI N/A
- APVO N/A
- Revenue Growth
- UPXI 4.75
- APVO N/A
- 52 Week Low
- UPXI $1.90
- APVO $0.60
- 52 Week High
- UPXI $22.53
- APVO $51.06
- Technical
- Relative Strength Index (RSI)
- UPXI 88.68
- APVO 30.74
- Support Level
- UPXI $9.81
- APVO $0.60
- Resistance Level
- UPXI $22.00
- APVO $0.80
- Average True Range (ATR)
- UPXI 2.41
- APVO 0.19
- MACD
- UPXI 1.41
- APVO 0.03
- Stochastic Oscillator
- UPXI 65.96
- APVO 6.97
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.